ASX Share rice
Wed 12 Aug 2020 - 04:17:am (Sydney)

1AD Share Price

ADALTA LIMITED1ADPharmaceuticals, Biotechnology & Life Sciences

1AD Company Information


AdAlta Limited





GIC Industry:


GIC Sub Industry:



2 Park Drive Bundoora VIC Australia 3083


61 3 9479 5159

CEO, MD & Director:

Dr. Timothy Charles Oldham

Chief Operating Officer:

Dr. Dallas Hartman

Chief Scientific Advisor & Chief Scientific Officer:

Prof. Michael Foley Ph.D.

Company Sec.:

Mr. Cameron Jones

Company Overview:

AdAlta Limited, a drug discovery and development company, develops protein therapeutics. The company focuses on developing its lead i-body drug candidate, AD-114, for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has a collaborative partnership with Excellerate Bioscience to advance the development of its i-body pipeline. AdAlta Limited was incorporated in 2006 and is based in Bundoora, Australia.

1AD Share Price Information

Shares Issued:


Market Capitalisation:


Revenue (TTM):


Revenue Per Share (TTM):


Earnings per Share:


Profit Margin:


Operating Margin (TTM):


Return On Assets (TTM):


Return On Equity (TTM):


Quarterly Revenue Growth (YOY):


Gross Profit(TTM):


Diluted Earnings Per Share (TTM):


1AD CashFlow Statement

CashFlow Date:




Change To Liabilities:


Total Cashflow From Investing Activities:


Net Income:


Total Cash From Operating Activities:




Change To Account Receivables:


Sale Purchase Of Stock:


Capital Expenditures:


1AD Income Statement

Income Date:


Income Before Tax:


Net Income:


Gross Profit:


Operating Income:


Other Operating Expenses:


Total Revenue:


Total Operating Expenses:


Cost Of Revenue:


1AD Balance Sheet

Balance Sheet Date:


Total Liabilities:


Total Stockholder Equity:


Other Current Liabilities:


Total Assets:


Common Stock:


Other Current Assets:


Retained Earnings:


Other Assets:




Total Current Liabilities:


Property - Plant & Equipment:


Net Tangible Assets:


Long-Term Investments:


Total Current Assets:


Net Receivables:


Short-Term Investments:


Accounts Payable:


Non Currrent Assets (Other):


Short-Term Investments:


Non Current Liabilities Total:


1AD Share Price History

1AD News

19 Oct, 2019
Every investor in AdAlta Limited (ASX:1AD) should be aware of the most powerful shareholder groups. Insiders often own...
09 Oct, 2019
MELBOURNE, Australia, Oct. 9, 2019 /PRNewswire/ -- The Board of AdAlta Limited (1AD.AX), is pleased to announce the appointment of experienced global pharmaceutical executive Dr Tim Oldham as Chief Executive Officer and Managing Director. Dr Oldham has extensive skills and expertise over his career in the industry in strategy and portfolio building, biologic therapies development and pipeline commercialisation.
16 Sep, 2019
AdAlta secures commercial agreement for its i-body platform with global medical technology and diagnostics firm, GE Healthcare. Under the licensing deal, the two companies will develop i-bodies for diagnostic imaging. AdAlta will screen its novel i-body library on a number of targets in order to identify i-bodies that GE can use as imaging agents, starting with Granzyme B.
05 Sep, 2019
Even the best stock pickers will make plenty of bad investments. Unfortunately, shareholders of AdAlta Limited...